A genetic basis for functional hypothalamic amenorrhea. by Caronia, L.M. et al.
  
Serveur Académique Lausannois SERVAL serval.unil.ch 
Author Manuscript 
Faculty of Biology and Medicine Publication 
This paper has been peer-reviewed but dos not include the final publisher 
proof-corrections or journal pagination. 
Published in final edited form as:  
 
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains 
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article. 
 
Title: A genetic basis for functional hypothalamic amenorrhea. 
Authors: Caronia LM, Martin C, Welt CK, Sykiotis GP, Quinton R, 
Thambundit A, Avbelj M, Dhruvakumar S, Plummer L, Hughes VA, 
Seminara SB, Boepple PA, Sidis Y, Crowley WF Jr, Martin KA, Hall JE, 
Pitteloud N 
Journal: The New England journal of medicine 
Year: 2011 Jan 20 
Volume: 364 
Issue: 3 
Pages: 215-25 
DOI: 10.1056/NEJMoa0911064 
 
A Genetic Basis for Functional Hypothalamic Amenorrhea
Lisa M. Caronia, B.A., Cecilia Martin, Ph.D., Corrine K. Welt, M.D., Gerasimos P. Sykiotis,
M.D., Ph.D., Richard Quinton, M.D., Apisadaporn Thambundit, B.A., Magdalena Avbelj,
M.D., Ph.D., Sadhana Dhruvakumar, M.Sc., Lacey Plummer, B.A., Virginia A. Hughes,
M.Sc., Stephanie B. Seminara, M.D., Paul A. Boepple, M.D., Yisrael Sidis, Ph.D., William F.
Crowley Jr., M.D., Kathryn A. Martin, M.D., Janet E. Hall, M.D., and Nelly Pitteloud, M.D.
Harvard Center for Reproductive Endocrine Sciences and Reproductive Endocrine Unit and the
Department of Medicine, Massachusetts General Hospital — both in Boston (L.M.C., C.M.,
C.K.W., G.P.S., A.T., M.A., S.D., L.P., V.A.H., S.B.S., P.A.B., Y.S., W.F.C., K.A.M., J.E.H., N.P.);
the Department of Endocrinology, Royal Victoria Infirmary, and the Institute for Human Genetics,
University of Newcastle upon Tyne — both in Newcastle upon Tyne, United Kingdom (R.Q.); and
the Endocrine Division, Centre Hospitalier Universitaire Vaudois, University of Lausanne,
Lausanne, Switzerland (Y.S., N.P.).
Abstract
BACKGROUND—Functional hypothalamic amenorrhea is a reversible form of gonadotropin-
releasing hormone (GnRH) deficiency commonly triggered by stressors such as excessive
exercise, nutritional deficits, or psychological distress. Women vary in their susceptibility to
inhibition of the reproductive axis by such stressors, but it is unknown whether this variability
reflects a genetic predisposition to hypothalamic amenorrhea. We hypothesized that mutations in
genes involved in idiopathic hypogonadotropic hypogonadism, a congenital form of GnRH
deficiency, are associated with hypothalamic amenorrhea.
METHODS—We analyzed the coding sequence of genes associated with idiopathic
hypogonadotropic hypogonadism in 55 women with hypothalamic amenorrhea and performed in
vitro studies of the identified mutations.
RESULTS—Six heterozygous mutations were identified in 7 of the 55 patients with
hypothalamic amenorrhea: two variants in the fibroblast growth factor receptor 1 gene FGFR1
(G260E and R756H), two in the prokineticin receptor 2 gene PROKR2 (R85H and L173R), one in
the GnRH receptor gene GNRHR (R262Q), and one in the Kall-mann syndrome 1 sequence gene
KAL1 (V371I). No mutations were found in a cohort of 422 controls with normal menstrual
cycles. In vitro studies showed that FGFR1 G260E, FGFR1 R756H, and PROKR2 R85H are loss-
of-function mutations, as has been previously shown for PROKR2 L173R and GNRHR R262Q.
CONCLUSIONS—Rare variants in genes associated with idiopathic hypogonadotropic
hypogonadism are found in women with hypothalamic amenorrhea, suggesting that these
mutations may contribute to the variable susceptibility of women to the functional changes in
GnRH secretion that characterize hypothalamic amenorrhea. Our observations provide evidence
for the role of rare variants in common multifactorial disease. (Funded by the Eunice Kennedy
Shriver National Institute of Child Health and Human Development and others; ClinicalTrials.gov
number, NCT00494169.)
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Reproduction is an energetically costly process for women, and defense mechanisms have
evolved that temporarily inhibit reproduction under adverse conditions. Stressors such as
weight loss,1 excessive exercise,2 eating disorders,3 and psychological distress4 sup-press
the hypothalamic–pituitary–gonadal axis by inhibiting hypothalamic pulsatile secretion of
gonadotropin-releasing hormone (GnRH).5 This frequent cause of female infertility is
diagnosed as functional hypothalamic amenorrhea, defined as the absence of menses, low or
normal gonadotropin levels, and hypoestrogenemia without organic abnormality.6
Hypothalamic amenorrhea is associated with a spectrum of abnormal GnRH-secretion
patterns, and administration of exogenous pulsatile GnRH can restore functionality of the
hypothalamic–pituitary–gonadal axis.7 The exquisite sensitivity of the GnRH pulse
generator to energy deficits is evidenced by the fact that serum levels of leptin, a signal of
fat reserves, are often low in patients with hypothalamic amenorrhea and that leptin
replacement can restore GnRH pulsatility.8-10 After the underlying stressors have been
eliminated, normal reproductive function resumes in most cases.11 Among both women and
female nonhuman primates, sensitivity to the inhibition of the hypothalamic–pituitary–
gonadal axis by such stressors varies substantially.12,13 However, it is unknown whether this
susceptibility reflects a genetic predisposition to hypothalamic amenorrhea.
Much is known about the genetics of congenital GnRH deficiency (idiopathic hypogonado-
tropic hypogonadism), in contrast to hypothalamic amenorrhea. Idiopathic
hypogonadotropic hypogonadism is characterized by an absence of puberty and by
infertility, caused by defects in the secretion of GnRH from the hypothalamus or defects in
the action of GnRH on the pituitary.14,15 The disease is genetically heterogeneous, with
several associated loci that account for approximately 40% of cases.15 The involved genes
encode proteins essential for GnRH neuron development and GnRH secretion and action.
16-18 The variable expressivity of the clinical features of GnRH deficiency most likely
reflects the contributions of multiple genetic defects or epigenetic perturbations. We
hypothesized that mutations in genes involved in idiopathic hypogonadotropic
hypogonadism confer susceptibility to the functional deficiency in GnRH secretion that
characterizes hypothalamic amenorrhea.
METHODS
STUDY PARTICIPANTS
All participants provided written informed consent.
Controls—Controls were 422 women from the greater Boston area, recruited by means of
advertising, who had undergone normal puberty (menarche at ≥10 but <15 years), had had a
normal menstrual cycle (27 to 32 days' duration) for the previous 2 years, and had a body-
mass index (BMI, the weight in kilograms divided by the square of the height in meters)
between 18 and 35. No predisposing factors for hypothalamic amenorrhea were reported for
375 of the 422 women; the remaining 47 exercised for more than 5 hours per week, which is
a pre-disposing factor.
Patients with Hypothalamic Amenorrhea—Hypothalamic amenorrhea was diagnosed
in 55 women presenting to the Massachusetts General Hospital or Newcastle upon Tyne
Hospital with a history of secondary amenorrhea for 6 months or more, low or normal
gonadotropin levels, low serum estradiol levels, and one or more predisposing factors. These
factors included excessive exercise (>5 hours per week),19 loss of more than 15% of body
weight, and a subclinical eating disorder as ascertained with the use of the Eating Attitudes
Test.20 None of the patients met the diagnostic criteria for anorexia nervosa at presentation.
21
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All 55 patients with hypothalamic amenorrhea had completed puberty spontaneously. The
mean (±SD) age at diagnosis was 22.4±6.1 years, and the mean BMI was 19.4±2.2. The
mean age at menarche was 13.5±1.8 years, with 13 patients reporting delayed menarche (age
at onset, ≥15 years) at a time when no factors predisposing them to hypothalamic
amenorrhea were present. Twenty-five patients reported exercising excessively, 20 had
weight loss, and 28 had a subclinical eating disorder characterized by dietary restriction and
preoccupation with weight.20,21 Six patients had a family history of delayed puberty, and 9
a family history of hypothalamic amenorrhea. The mean serum levels of luteinizing
hormone (LH), follicle-stimulating hormone (FSH), and estradiol in the group with
hypothalamic amenorrhea were 4.1±3.0 IU per liter, 6.7±3.3 IU per liter, and 39±25 pg per
milliliter (143±92 pmol per liter), respectively. All patients had normal results on
neuroimaging, and none had symptoms or biochemical signs of the polycystic ovary
syndrome (hirsutism, acne, hyperandrogenemia, an LH-to-FSH ratio >1). A subgroup of the
patients underwent LH-secretion studies involving blood sampling every 10 minutes over a
24-hour period.11,22
Patients with Idiopathic Hypogonadotropic Hypogonadism—We evaluated 160
women with idiopathic hypogonadotropic hypogonadism. All had absent or incomplete
puberty as of 18 years of age, low or normal serum gonadotropin levels, low serum estradiol
levels, otherwise normal anterior pituitary function, and normal results on neuroimaging.
GENETIC STUDIES
Genomic DNA was extracted from peripheral-blood samples obtained from all participants.
Exonic and proximal intronic sequences (located at least 15 bp from the splice sites) of
seven genes implicated in the cause of idiopathic hypogonadotropic hypogonadism were
determined in all samples from patients with hypothalamic amenorrhea: the Kallmann
syndrome 1 sequence gene KAL1,23 the GnRH receptor gene GNRHR,24 the G protein–
coupled receptor 54 gene GPR54,25 the fibroblast growth factor receptor 1 gene FGFR1,26
the fibroblast growth factor 8 gene FGF8,27 the prokineticin 2 gene PROK2,28 and the
prokineticin receptor 2 gene PROKR2.29 Sequence variations were found on both strands
and were confirmed in separate polymerase-chain-reaction assays. No rare sequence variants
were found in a cohort of 422 controls with normal menstrual cycles.
FUNCTIONAL CHARACTERIZATION OF NEW FGFR1 AND PROKR2 MUTATIONS
Gene-Reporter Assays—The FGFR1 G260E and R756H mutations and the PROKR2
R85H mutation were introduced into previously described expression vectors by means of a
QuickChange XLII Kit (Stratagene)28,29 and were studied in L6 myoblasts and human
embryonic kidney (HEK) 293 cells, respectively. The ability to activate downstream
signaling was compared between the mutated receptor and its wild-type counterpart in
transient transfection assays, as previously described.29,30 The osteocalcin fibroblast
growth factor (FGF) response element (OCFRE) reporter and the murine early growth
response 1 (Egr-1) reporter served as indicators of FGFR1-induced and PROKR2-induced
mitogen-activated protein kinase (MAPK) signaling, respectively. Each assay was
performed twice in triplicate. Four-parameter sigmoidal dose–response curves were
generated and analyzed with the use of Prism 4 statistical software (GraphPad).
Total Expression and Cell-Surface–Receptor Expression—Total expression of
wild-type and mutant FGFR1 and PROKR2 transfected into COS-7 cells was determined by
means of Western blotting involving whole-cell extracts, as previously described.29,30 The
cell-surface expression of FGFR1 was quantified as previously described,30 and the cell-
surface expression of PROKR2 was also quantified, with the use of a 3xHA tag sequence
fused with the N-terminal end of PROKR2 to facilitate recognition by the antibody (Clone
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HA-7, Sigma). Antibody-binding assays were performed three times in quadruplicate.
Expression levels of mutant and wild-type receptors were compared by means of Student's
two-tailed t-test.
RESULTS
Heterozygous mutations in genes associated with idiopathic hypogonadotropic
hypogonadism (FGFR1, PROKR2, GNRHR, and KAL1) were identified in 7 of the 55
patients with hypothalamic amenorrhea (13%; 95% confidence interval, 5 to 24) (Fig. 1 and
Table 1). All 7 patients were white, as reported by study physicians. These genetic variants
were absent among the controls (the 375 women without risk factors for hypothalamic
amenorrhea and the 47 women who exercised >5 hours per week). The variants alter amino
acids that are highly conserved across species (Fig. 2C, 2D, and 2E) and cause considerable
loss of function,29,31,32 findings that are consistent with disease-associated mutations.
FGFR1 mutants (G260E and R756H) in the ligand domain and tyrosine kinase domain of
the receptor, respectively, were found in Patients 1 and 2. The FGFR1 G260E and R756H
mutants showed expression levels similar to those of wild-type FGFR1, both overall (Fig. 2F
and 2G) and on the cell surface (Fig. 2I and 2J). However, results of a transcriptional assay
show that the G260E and R756H mutants result in loss of function, as demonstrated by a
decrease in FGF-induced MAPK reporter activity (reflected by OCFRE activity) (P<0.001)
(Fig. 2L and 2M).
The PROKR2 mutant R85H identified in Patient 3 is also a loss-of-function mutant, as
evidenced by decreased overall and cell-surface expression decreased signaling activity as
compared wild-type PROKR2 (P<0.001 for cell-surface expression and signaling activity)
(Fig. 2H, and 2N).31 The PROKR2 L173R mutant seen Patient 4 and the GNRHR R262Q
mutant in Patients 5 and 6 have previously been reported loss-of-function mutants (Table 2).
29,31,32 Finally, characteristics of the KAL1 V371I mutant in Patient 7 could not be assessed
(Table 2) owing the scarcity of in vitro functional assays available for KAL1.
All seven patients with hypothalamic amenorrhea who had mutations had secondary
amenorrhea for at least 6 months and at least one factor for hypothalamic amenorrhea (Table
Four of the seven reported a family history of hypothalamic amenorrhea or delayed puberty
(Fig. 1 and Table 2). Among the seven patients, the age at diagnosis ranged from 18 to 34
years (mean, 24.4±6.2), and the BMI at diagnosis ranged from 18 to 22 (mean, 19.4±1.9).
Four of the seven patients had attempted to conceive; three of the attempts were successful,
with one patient conceiving without assisted reproductive treatment. Two of the seven
patients continued to receive long-term hormone-replacement therapy. The other five
discontinued hormonal therapy and had recovery of menses. A more detailed summary of
the seven patients is given in the Supplementary Appendix (available with the full text of
this article at NEJM.org).
Our patients with hypothalamic amenorrhea who had the PROKR2 R85H or FGFR1 R756H
mutation also had abnormal patterns of endogenous GnRH-induced LH secretion (Fig. 3).
DISCUSSION
We found genetic defects in several patients with hypothalamic amenorrhea. The affected
genes play fundamental roles in GnRH ontogeny and function: GNRHR encodes the unique
receptor that is activated by gonadotropin-releasing hormone 1 (GnRH1) in the pituitary33;
KAL1 and PROKR2 are critical for the migration of GnRH-secreting neurons34,35; and
FGFR1 controls the fate specification, migration, and survival of GnRH-secreting neurons.
17 In humans, mutations in these genes underlie severe congenital GnRH deficiency
Caronia et al. Page 4
N Engl J Med. Author manuscript; available in PMC 2011 July 20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(idiopathic hypogonadotropic hypogonadism).15 In fact, the GNRHR R262Q mutation and
the PROKR2 R85H and L173R mutations described here have previously been associated
with idiopathic hypogonadotropic hypogonadism.29,31,32,36,37
Patients who had hypothalamic amenorrhea as well as the PROKR2 R85H or FGFR1
R756H mutation in our study were also shown to have abnormal patterns of endogenous
GnRH-induced LH secretion, as previously described in women with hypothalamic
amenorrhea.7 We speculate that decreased PROKR2 or FGFR1 signaling leads to a partially
compromised GnRH neuronal network owing to a smaller-than-normal number of GnRH-
producing cells that have successfully completed embryonic migration to the hypothalamus,
a suboptimal maturation of the GnRH network during puberty, or a defective regulation of
GnRH secretion — since both proteins are expressed not only during development but also
in the adult hypothalamus.16,28 This would, in turn, predispose persons to abnormal GnRH
secretion under the influence of factors that stress the reproductive system. FGFR1 and
PROKR2 signaling also modifies eating behavior in mice.38,39 Thus, we speculate that
genetic defects in these pathways may also contribute to the abnormal eating patterns seen in
many patients with hypothalamic amenorrhea.
We found that genes mutated in patients with idiopathic hypogonadotropic hypogonadism
also are mutated in those with hypothalamic amenorrhea. This finding expands our
understanding of the genetics of GnRH-deficiency disorders. Idiopathic hypogonadotropic
hypogonadism was traditionally considered a genetically determined, congenital, and
lifelong form of GnRH deficiency. However, as many as 10% of patients with idiopathic
hypogonadotropic hypogonadism resume normal reproductive function after treatment is
discontinued, even if they have genetic defects.40 This reversal of idiopathic hypogonado-
tropic hypogonadism indicates the plasticity of the GnRH network and its sensitivity to
nongenetic factors. Conversely, idiopathic hypogonadotropic hypogonadism occasionally is
present in adult men (in which case it is called adult-onset idiopathic hypogonadotropic
hypogonadism).41 Some men with the disease who carry mutations in genes underlying
idiopathic hypogonadotropic hypogonadism27 have normal reproductive function before
onset, suggesting that their GnRH deficiency results from a combination of genetic and
environmental influences.
In contrast to idiopathic hypogonadotropic hypogonadism, hypothalamic amenorrhea has
been traditionally viewed as a functional form of GnRH deficiency resulting from
insufficient energy availability, psychological stress, or both. Studies of humans and
nonhuman primates have shown that stress can induce reproductive dys-function, including
amenorrhea, in many, although not all, females with normal menstrual cycles.12,13,19 Our
findings may help to explain the variable susceptibility of women to inhibition of the
hypothalamic-pituitary-gonadal axis. Since patients with mutations resumed regular menses
after discontinuing hormone-replacement therapy, the genetic component of hypothalamic
amenorrhea predisposes one to, but is not sufficient to cause, GnRH deficiency.
If hypothalamic amenorrhea has a genetic basis partially in common with idiopathic
hypogonadotropic hypogonadism, what are the factors that ultimately generate these
divergent clinical phenotypes? The total load of mutations in genes related to GnRH
ontogeny and action might be less in hypothalamic amenorrhea than in idiopathic
hypogonadotropic hypogonadism. Patients with idiopathic hypogonadotropic hypogonadism
frequently show homozygosity and compound heterozygosity for mutations at the disease-
causing loci.25,32,36,42 Furthermore, digenic inheritance of mutations associated with
idiopathic hypogonadotropic hypogonadism (FGFR1 in combination with GNRHR,NELF
[the gene encoding the nasal embryonic LH-releasing hormone factor], or PROKR2, or other
digenic pairs) has been reported.30,36,37,43
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All six mutations associated with hypothalamic amenorrhea in our study were heterozygous.
We speculate that such heterozygous mutations, while not sufficient to cause idiopathic
hypogonadotropic hypogonadism, could set a lower threshold for functional inhibition of the
hypothalamic–pituitary–gonadal axis under adverse hormonal, nutritional, or psychological
conditions and thereby lead to hypothalamic amenorrhea. Such a lower threshold for
inhibition might also confer a selective advantage to female carriers during famine, helping
to balance survival against the metabolic needs of pregnancy. This explanation would be
consistent with the presence of mutations associated with idiopathic hypogonadotropic
hypogonadism and hypothalamic amenorrhea in persons who do not have symptoms. The
PROKR2 L173R mutation appears to be an example: it has been reported in more than a
dozen patients with idiopathic hypogonadotropic hypogonadism, mostly in the heterozygous
state, and in many of these cases was inherited from an asymptomatic parent.9,31,36,37
To elucidate the genetics of hypothalamic amenorrhea more completely, it will be important
to undertake comprehensive sequencing of the genes associated with idiopathic
hypogonadotropic hypogonadism in larger cohorts of patients with hypothalamic
amenorrhea. Twenty-five percent of women with hypothalamic amenorrhea in our study had
a history of delayed puberty, which is frequently seen in family members of patients with
idiopathic hypogonadotropic hypogonadism. It may be worthwhile to investigate whether
rare variants in genes underlying idiopathic hypogonadotropic hypogonadism or
hypothalamic amenorrhea also contribute to delayed puberty.
Genetic defects within pathways controlling appetite or stress-response systems might also
contribute to hypothalamic amenorrhea. The genetic susceptibility to anorexia or bulimia
nervosa has been investigated in several association studies that examined candidate genes
such as brain-derived neurotrophic factor, neurotrophic tyrosine kinase receptor types 2 and
3, serotonin, leptin, and hypocretin.44,45 Unlike our study, which sought rare genetic
variants, the prior studies focused on common DNA polymorphisms. The results have been
largely inconclusive, most likely owing to small sample sizes, heterogeneity in race and
ethnic group, and variation in diagnostic criteria. It might prove more fruitful to investigate
whether rare variants in genes associated with the response to stress and starvation also
contribute to susceptibility to hypothalamic amenorrhea.
In conclusion, we demonstrated that patients with hypothalamic amenorrhea have mutations
in genes regulating GnRH ontogeny and action. Given the limited size of the cohort with
hypothalamic amenorrhea, we would not recommend that women with hypothalamic
amenorrhea be routinely screened for mutations at loci known to underlie idiopathic
hypogonadotropic hypogonadism, except in cases of clear familial inheritance of
hypothalamic amenorrhea or idiopathic hypogonadotropic hypogonadism. Further
elucidation of the genetic basis of hypothalamic amenorrhea and delineation of the
relationship among genotype, environment, and phenotype are needed.
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Figure 1. Pedigrees of the Seven Patients with Hypothalamic Amenorrhea (HA) Found to Have
Mutations
For each pedigree, the patient with the mutation is indicated by a red arrow. The mutated
gene is indicated in bold to the left of the pedigree, and the allele status is given below the
proband or affected family members, with plus signs indicating wild-type and G260E,
R756H, R85H, L173R, R262Q, and V371I indicating the amino acid mutations. Squares
indicate male family members, circles female family members, and diamonds offspring
whose sex is not shown (with the numbers of persons given within the diamond).
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Figure 2. Loss-of-Function Mutations in Patients with Hypothalamic Amenorrhea
Panels A and B show the structures of FGFR1 and PROKR2, respectively, as well as the
mutations of interest. Panels C, D, and E show that the FGFR1 G260 and R756 amino acids
and the PROKR2 R85 amino acid are highly conserved across vertebrate species. Panels F,
G, and H show that the overall expression levels of FGFR1 G260E and R756H were normal,
whereas PROKR2 R85H expression levels were decreased (P<0.01), as compared with wild-
type levels. Heat-shock protein 90 (HSP90) was a positive control for gel loading. An empty
vector (EV) was used as a negative control for protein expression. Panels I, J, and K show
that the receptor cell-surface expression levels in COS-7 cells were similar to the wild-type
levels for both FGFR1 mutants but were significantly decreased for PROKR2 R85H
(P<0.001). Panels L, M, and N show that the FGFR1 G260E mutant has decreased fibro-
blast growth factor 8 (FGF8)-induced osteocalcin FGF response element (OCFRE) activity
as compared with the wild type (P<0.001), that the FGFR1 R756H mutant has decreased
FGF2-induced OCFRE activity as compared with the wild type (P<0.001), and that the
PROKR2 R85H mutant has decreased PROK2-induced early growth response 1 (Egr-1)
activity as compared with the wild type (P<0.001). D1, D2, and D3 denote the ligand-
binding domains of FGFR1; Luc the lucifer-ase reporter vector; and TM the transmembrane
domain of FGFR1. T and I bars indicate standard errors of the means of two experiments
performed in triplicate for the gene-reporter assays or the means of three experiments
performed in quadruplicate for the antibody-binding assays.
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Figure 3. Patterns of Luteinizing Hormone (LH) Secretion over a 24-Hour Period, According to
Mutation Status
The pattern of LH secretion induced by endogenous gonadotropin-releasing hormone in the
early follicular phase of the menstrual cycle is shown as a normal, pulsatile pattern in a
healthy woman (Panel A), as apulsatile in a patient with hypothalamic amenorrhea and the
FGFR1 R756H mutation (Panel B), and as both apulsatile and pulsatile with increasing
amplitude during the night in a patient with the PROKR2 R85H mutation (Panel C).
Arrowheads indicate peaks in secretion (of which there are none in the apulsatile pattern in
Panel B). Mean levels of LH, follicle-stimulating hormone (FSH), and estradiol are listed for
the two patients. To convert values for estradiol to picomoles per liter, multiply by 3.671.
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